Poate AI proiecta un compus medicamentos care se leagă de un anumit țintă proteic fără date experimentale anterioare ?

În mod tradițional, descoperirea de medicamente se bazează pe experimente extensive în laborator și testări iterative pentru a identifica compuși viabili. Modelele recente de inteligență artificială, precum cele care utilizează abordări generative bazate pe difuzie, pot propune acum noi structuri moleculare adaptate la ținte biologice specifice. Această capacitate accelerează etapele incipiente ale cercetării farmaceutice și reduce dependența de screeningul forțat.

Background

Traditionally, drug discovery relies on extensive lab experiments and iterative testing to identify viable compounds. Recent AI models, such as those using diffusion-based generative approaches, can now propose novel molecular structures tailored to specific biological targets. This capability accelerates the early stages of pharmaceutical research and reduces reliance on brute-force screening.

AI can propose novel drug-like compounds that bind a specified protein target even when no prior experimental data exist, using structure-based deep learning methods such as RFdiffusion or diffusion models trained on protein-ligand complexes to generate chemically plausible molecules and docking scores without wet-lab feedback. These generative models learn the rules of molecular binding from large structural databases and propose candidates that fit the target’s binding pocket, though their designs still require downstream biochemical validation to confirm affinity, selectivity, and drug-like properties (Nature, Enriched May 12, 2026).

The latest systems integrate evolutionary search or reinforcement learning to refine potency and ADMET (absorption, distribution, metabolism, excretion, and toxicity) profiles, increasing the fraction of synthetically accessible, high-scoring hits that can enter experimental testing. Because no 3D structure is strictly necessary, sequence-based models like AlphaFold-informed pocket predictions can also guide ligand design when an experimental structure is unavailable.